CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient

Core Insights - CERo Therapeutics Holdings, Inc. is presenting data from its Phase 1 clinical trial, CERTAIN-T, for its lead compound CER-1236, which shows a positive safety profile and significant in vivo cell expansion [1][2] - The trial includes patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), demonstrating promising results such as transfusion independence in an index patient [1][3] Company Overview - CERo is an innovative cellular immunotherapy company focused on developing next-generation engineered T cell therapeutics for cancer treatment [5] - The company’s approach integrates innate and adaptive immunity to enhance tumor targeting, utilizing a novel platform referred to as Chimeric Engulfment Receptor T cells (CER-T) [5][6] Clinical Trial Details - The Phase 1/1b study is designed to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory AML or newly diagnosed TP53 mutated AML [3] - The trial has been amended to include transfusion-dependent myelodysplastic syndromes (TD-MDS) and high-risk MDS (HR-MDS) based on emerging safety data [3][4] Safety and Efficacy Observations - Early clinical findings indicate a favorable safety and tolerability profile for CER-1236, with no dose-limiting toxicities or observed cytokine release syndrome (CRS) in the initial patients [2][4] - The trial's primary outcome measures include the incidence of adverse events, dose-limiting toxicities, and overall response rates [3]